TScan Therapeutics Inc. (TCRX) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    TScan Therapeutics Inc.

    NASDAQ: TCRX · Real-Time Price · USD
    1.75
    -0.10 (-5.41%)
    At close: Sep 12, 2025, 12:24 PM

    TScan Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 2.82M 21.05M 13.54M 10.14M
    Cost of Revenue
    		 4.11M 88.15M 5.14M 3.33M
    Gross Profit
    		 2.82M -67.1M 8.4M 6.81M
    Operating Income
    		 -134.82M -93.46M -66.64M -48.64M
    Interest Income
    		 12.06M 8M 1.59M 16K
    Pretax Income
    		 -127.5M -89.22M -66.22M -48.63M
    Net Income
    		 -127.5M -89.22M -65.81M -48.63M
    Selling & General & Admin
    		 29.56M 26.35M 20.35M 13.83M
    Research & Development
    		 107.35M 88.15M 59.82M 44.95M
    Other Expenses
    		 728K n/a 1.59M 16K
    Operating Expenses
    		 137.64M 114.51M 80.17M 58.78M
    Interest Expense
    		 3.65M 3.76M 1.18M n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 137.64M 114.51M 80.17M 58.78M
    Income Tax Expense
    		 n/a n/a -415K n/a
    Shares Outstanding (Basic)
    		 111.99M 65.6M 24.05M 23.91M
    Shares Outstanding (Diluted)
    		 111.99M 65.6M 24.05M 23.91M
    EPS (Basic)
    		 -1.14 -1.36 -2.74 -2.03
    EPS (Diluted)
    		 -1.14 -1.36 -2.74 -2.03
    EBITDA
    		 -119.74M -80.1M -59.91M -45.3M
    EBIT
    		 -123.85M -85.46M -65.05M -48.63M
    Depreciation & Amortization
    		 4.11M 5.36M 5.14M 3.33M

    Add to Watchlist